9804 Medical Center Drive
Rockville, MD 20850
United States
240 552 8181
https://www.regenxbio.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 344
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Kenneth T. Mills | President, CEO & Director | 1M | 720,99k | 1975 |
Mr. Vittal K. Vasista | Executive VP & CFO | 666,5k | 573,3k | 1968 |
Mr. Curran M. Simpson M.S. | Executive VP & COO | 698,6k | S.O. | 1962 |
Dr. Olivier Danos Ph.D. | Executive VP & Chief Scientific Officer | 778,85k | S.O. | 1958 |
Dr. Stephen Pakola M.D. | Executive VP & Chief Medical Officer | 674,05k | S.O. | 1969 |
Mr. Patrick J. Christmas II, J.D. | Executive VP & Chief Legal Officer | 1,11M | 1,29M | 1971 |
Ms. Shiva G. Fritsch | Chief Communications & People Officer | S.O. | S.O. | S.O. |
Dr. Laura A. Coruzzi J.D., Ph.D. | Executive Vice President of Intellectual Property | S.O. | S.O. | 1954 |
Dr. Ram Palanki Pharm.D. | Executive VP of Commercial Strategy & Operations | S.O. | S.O. | 1976 |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
L’ISS Governance QualityScore de REGENXBIO Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 3; Société : 8; Droits des actionnaires : 8; Compensation : 8.